Viatris awaits July 30 FDA decision on low-dose estrogen contraceptive patch
The 505(b)(2) filing rests on a completed Phase 3 trial that already reported a 4.14 Pearl Index, leaving the label and any FDA follow-up requests as the open questions.
Executive Summary
- The FDA is set to act on Viatris's application for a new low-dose estrogen contraceptive patch, with the clinical evidence behind the filing already reported and positive.
- The pivotal study met its enrollment target and produced a contraceptive efficacy result and safety profile that the sponsor has already disclosed, ahead of the regulatory decision now pending.
- The trial's primary completion date moved over the course of the study before finishing on schedule against its final guidance, a pattern of protocol churn that is common for a multi-year contraceptive efficacy study and did not prevent the trial from completing with its enrollment target intact.
- The product enters a contraception field saturated with small-molecule hormonal options, none of which share its specific transdermal low-dose estrogen formulation, positioning it as a lifecycle variant rather than a novel mechanism.
The decision ahead
The U.S. Food and Drug Administration has assigned a target action date of July 30, 2026 for Viatris Inc.'s New Drug Application for MR-100A-01, a low-dose estrogen combined hormonal contraceptive weekly patch, filed under the 505(b)(2) pathway (an application that can rely in part on existing safety and efficacy data). The FDA accepted the filing for review on May 1, 2026. The application is a lifecycle successor to Viatris's existing Xulane patch, according to the sponsor's own characterization of the program. ViatrisViatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific MeetingMay 1, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the pivotal trial showed
The application rests on NCT05139121, a Phase 3 trial that enrolled 1,319 healthy, post-menarcheal, premenopausal women of childbearing potential across the United States, Canada, and Puerto Rico, evaluating contraceptive efficacy over up to thirteen 28-day cycles. The trial completed on January 15, 2025, having enrolled to its target of 1,319. Viatris disclosed on May 8, 2025 that the study produced a Pearl Index (a standard annualized pregnancy-rate measure) of 4.14 and a cumulative pregnancy rate of 3.7% over 13 cycles, with complete patch detachment in 1.3% of cycles and severe local skin reactions in under 1%. The company called the safety findings favorable and reported no new safety concerns. NCT05139121Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 CyclesNCT05139121
The timeline behind the filing
The trial's primary completion date shifted three times over its course, from May 2023 to September 2023 to January 2025, before the study finished in January 2025 against its final guidance. Enrollment moved from an original count near 1,200 to 1,321 and then settled at 1,319 as the study closed. Those changes track a multi-year efficacy study whose completion date and enrollment count both landed within range of their most recent registry guidance by the time the trial closed. Viatris said in May 2025 it planned to submit the NDA in the second half of 2025; the FDA's acceptance of that filing followed in May 2026, ahead of the current PDUFA window. NCT05139121+1Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 CyclesNCT05139121Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific MeetingMay 1, 2026
Where it sits competitively
The contraception field carries a wide roster of small-molecule hormonal comparators, including progestin- and estrogen-based products from Bayer, Organon, Insud Pharma, and Estetra, none of which share MR-100A-01's specific low-dose estrogen transdermal formulation as a direct match. MR-100A-01 is not a first-in-class mechanism; it is a same-class entrant competing on dose and delivery within an established hormonal contraceptive category. Its differentiation case rests on the lower estrogen dose and the patch's adhesion data, both of which Viatris highlighted separately in adhesion and pharmacokinetic abstracts presented at the 2026 ACOG Annual Clinical & Scientific Meeting. ViatrisViatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific MeetingMay 1, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.